Post-mastectomy Radiotherapy Reduces Risk for Locoregional Failure, Recurrence

Share this content:
Treatment with post-mastectomy radiotherapy reduces the risk for locoregional failure (LRF) recurrence and mortality.
Treatment with post-mastectomy radiotherapy reduces the risk for locoregional failure (LRF) recurrence and mortality.

Treatment with post-mastectomy radiotherapy (PMRT) reduces the risk for locoregional failure (LRF) recurrence and mortality among patients with T1-2 breast cancer and 1 to 3 positive axillary nodes, according to a guideline update published in the Journal of Clinical Oncology. 1

A joint panel consisting of members from the American Society of Clinical Oncology (ASCO), the American Society for Radiation Oncology, and the Society of Surgical Oncology evaluated a systematic literature review conducted by Cancer Care Ontario to develop an update on the ASCO guideline regarding PMRT.

While the panel was in “unanimous” agreement that PMRT reduces LRF, recurrence, and mortality upon reviewing the available evidence, they also stated that some subsets of patients are at such low risk for LRF that any benefit of the treatment modality is outweighed by potential toxicities. They agreed that clinicians who make recommendations for PMRT should consider factors that reduce the risk for LRF and increase the risk for complications.

RELATED: Q&A With Dr Sarah Vinnicombe: Use Breast MRI Judiciously for Optimal Outcomes

Upon positive sentinel node biopsy, if clinicians and patients decide to omit axillary dissection, the panel recommends that these patients receive PMRT only when there is sufficient information to justify its use without needing to know if additional axillary nodes are involved.

Treatment with PMRT is recommended to be administered to internal mammary nodes and supraclavicular-axillary apical nodes, as well as the chest wall or reconstructed breast.

Reference

  1. Recht A, Comen EA, Fine RE, et al. Postmastectomy radiotherapy: an American Society of Clinical Oncology, American Society for Radiation Oncology, and Society of Surgical Oncology focused guideline update. J Clin Oncol. 2016 Sep 19. doi: 10.1200/JCO.2016.69.1188 [Epub ahead of print.]

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs

Sign Up for Free e-newsletters